Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06297226 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Study acronym: QUINTESSENTIAL
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 9 words Secondary endpoints: details revised at 1 of 17 entries · Site details revised at 4 of 52 sites Show 2 more changesShow less
    • Secondary endpoints: details revised at 1 of 17 entries
    • Site details revised at 4 of 52 sites
  2. Primary completion date changed from estimate of Jun 30, 2027 to Jul 31, 2026 Site details revised at 8 of 52 sitesv27 Show 1 more changeShow less
    • Site details revised at 8 of 52 sites
  3. Study sites revised (52)v26 See this version in full on ClinicalTrials.gov ↗
  4. Study sites revised (52)v25 See this version in full on ClinicalTrials.gov ↗
  5. Study sites revised (52)v24 See this version in full on ClinicalTrials.gov ↗
Show 22 earlier versionsHide 22 earlier versions
  1. Primary endpoint revised Enrollment target: 175 to 230 · Interventions: Arlocabtagene Autoleucel (BMS-986393) (Biological) to Arlocabtagene Autoleucel (Biological) · Eligibility criteria expanded, about 20 words · 2 morev23 Show 5 more changesShow less
    • Enrollment target: 175 to 230
    • Interventions: Arlocabtagene Autoleucel (BMS-986393) (Biological) to Arlocabtagene Autoleucel (Biological)
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: 18 to 17
    • Study arms: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites revised (52)v22 See this version in full on ClinicalTrials.gov ↗
  3. Study sites revised (52)v21 See this version in full on ClinicalTrials.gov ↗
  4. Study sites revised (52)v20 See this version in full on ClinicalTrials.gov ↗
  5. Study sites revised (52)v19 See this version in full on ClinicalTrials.gov ↗
  6. Study sites revised (52)v18 See this version in full on ClinicalTrials.gov ↗
  7. Study sites: 48 to 52v17
  8. Primary endpoint revised Enrollment target: 150 to 175 · Interventions: BMS-986393 (Biological) to Arlocabtagene Autoleucel (BMS-986393) (Biological) · Eligibility criteria shortened, about 7 words · 3 morev16 Show 6 more changesShow less
    • Enrollment target: 150 to 175
    • Interventions: BMS-986393 (Biological) to Arlocabtagene Autoleucel (BMS-986393) (Biological)
    • Eligibility criteria shortened, about 7 words
    • Secondary endpoints: 23 to 18
    • Study sites revised (48)
    • Study title expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  9. Study sites: 47 to 48v15
  10. Primary completion date: Oct 2, 2026 to Jun 30, 2027 Completion date: Jun 4, 2030 to Jun 30, 2032 · Study sites revised (47)v14 Show 2 more changesShow less
    • Completion date: Jun 4, 2030 to Jun 30, 2032
    • Study sites revised (47)

    See this version in full on ClinicalTrials.gov ↗

  11. Secondary endpoints revised (23) Study sites revised (47) · Eligibility criteria shortened, about 3 wordsv13 Show 2 more changesShow less
    • Study sites revised (47)
    • Eligibility criteria shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  12. Study sites revised (47)v12 See this version in full on ClinicalTrials.gov ↗
  13. Study sites: 43 to 47v11
  14. Study sites: 42 to 43v10
  15. Study sites revised (42)v9 See this version in full on ClinicalTrials.gov ↗
  16. Study sites revised (42)v8 See this version in full on ClinicalTrials.gov ↗
  17. Study sites: 37 to 42v7
  18. Study sites: 36 to 37v6
  19. Study sites revised (36)v5 See this version in full on ClinicalTrials.gov ↗
  20. Study sites revised (36)v4 See this version in full on ClinicalTrials.gov ↗
  21. Trial status: Not Yet Recruiting to Recruiting Study sites: 25 to 36 · Start date changed from estimate of Apr 15, 2024 to Mar 21, 2024 · Eligibility criteria revised · 1 morev3 Show 4 more changesShow less
    • Study sites: 25 to 36
    • Start date changed from estimate of Apr 15, 2024 to Mar 21, 2024
    • Eligibility criteria revised
    • Secondary endpoints revised (23)

    See this version in full on ClinicalTrials.gov ↗

  22. Eligibility criteria revised Secondary endpoints revised (23)v2 Show 1 more changeShow less
    • Secondary endpoints revised (23)

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Trial Details
NCT Number NCT06297226
Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Conditions Multiple Myeloma
Enrollment 230 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov